FDA Approves Verelan PM For Essential Hypertension
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Verelan PM For Essential Hypertension

DUBLIN, IRELAND and MEQUON, WI -- Nov. 30, 1998 – The United States Food and Drug Administration has approved Schwarz Pharma, Inc.’s Verelan(R) (verapamil HCl) PM, a chronotherapeutic form of verapamil hydrochloride, for the management of essential hypertension.

Verelan PM, a calcium channel blocker, is designed for bedtime dosing and incorporates a four to five hour delay in drug delivery. The controlled onset delivery system results in a maximum plasma concentration of verapamil in the morning hours.

The most frequently reported side effects of verapamil are constipation, headache and dizziness, which can be easily managed in most patients.

Related Links: Verelan, Schwarz Pharma, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities